Regeneron Pharmaceuticals Inc. convinced the First Circuit to impose a higher causation standard in the government’s False Claims Act case alleging a drug kickback scheme, according to a Tuesday ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

WHO IS LUIGI MANGIONE?' premieres on Monday, February 17 at 8/7c on Investigation Discovery and will stream on Max ...

If there's one thing we know about rebrands, it's that many consumers hate change. From the biggest branding evolutions to ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

More info A man who was savagely attacked by convicted Limerick brothers Cian and Daragh Hayes said that, in his opinion, the Kildimo siblings deserved longer sentences than what they received ...

Regeneron Pharmaceuticals beat fourth-quarter ... reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via ...